Choice Stays Bullish on Unnamed Pharma Play as Semaglutide Rollout Targets India, Canada, Brazil in FY27

Analyst frames Q4 FY26 earnings drag as one-off, citing GLP-1 pipeline across three markets; Canada flagged as standout due to limited Indian generic competition—launch timelines and moat claims unverified.

bt-corporate · 7/9/2026, 7:48:34 AM · Ask about this →